Could a Staph Vaccine Be on the Horizon?

Genetic Engineering and Biotechnology News | December 26, 2019

Over the past several years staph infections have moved from the seemingly innocuous to some of the most serious threats to public health—mainly due to the rapid rise in drug resistance. Attempts to develop a vaccine against methicillin-resistant Staphylococcus aureus (MRSA) have failed to outsmart the superbug’s ubiquity and adaptability to antibiotics. However now, a new study from investigators at Washington University School of Medicine (WUSM) in St. Louis may help explain why previous attempts to develop a staph vaccine have failed, while also suggesting a new approach to vaccine design. Findings from the new study—published recently in the Journal of Clinical Investigation through an article titled “Staphylococcus aureus a-toxin suppresses antigen-specific T cell responses”— focuses on activating an untapped set of immune cells, as well as immunizing against staph in utero or within the first few days after birth.

Spotlight

Instant coffee, processed cheese, square sandwich ham - behind every supermarket product is a process and behind every process is a scientific breakthrough. In this entertaining and thought-provoking programme, farmer and TV personality Jimmy Doherty unpacks the science behind the food items we buy every day - from stay-fresh bread to soft scoop ice cream. Working from a makeshift science lab inside a barn, Jimmy carries out experiments to uncover the secrets of food technology. Exploding myths and revealing the little-known processes of food production, Jimmy's Food Factory will change the way you think about food.

Spotlight

Instant coffee, processed cheese, square sandwich ham - behind every supermarket product is a process and behind every process is a scientific breakthrough. In this entertaining and thought-provoking programme, farmer and TV personality Jimmy Doherty unpacks the science behind the food items we buy every day - from stay-fresh bread to soft scoop ice cream. Working from a makeshift science lab inside a barn, Jimmy carries out experiments to uncover the secrets of food technology. Exploding myths and revealing the little-known processes of food production, Jimmy's Food Factory will change the way you think about food.

Related News

Research Solutions Announces Partnership with BIO Business Solutions to Bring One-Click Scientific Literature Access to the Biotech Industry

Research Solutions | October 12, 2020

Research Solutions/Reprints Desk (NASDAQ: RSSS), a pioneer in providing cloud-based workflow solutions for R&D driven organizations, today announced that it has partnered with BIO Business Solutions to help life sciences companies save time and money on scholarly literature access via its award-winning Article Galaxy research platform. Operated by the Biotechnology Innovation Organization (BIO), BIO Business Solutions is the industry's largest cost savings purchasing program. More than 4,500 member companies worldwide—including biotechnology and biopharmaceutical firms, medical device firms, academic institutions, state biotechnology centers, and related organizations—together save more than $511 million annually through the BIO Business Solutions® program.

Read More

MEDICAL

TrialSpark, Committs to Improve Speed, Quality, and Innovation of Clinical Trials, Announces Collaboration with Aditum Bio

TrialSpark | December 21, 2020

TrialSpark, a tech-enabled drug development accomplice focused on improving the speed, quality, and innovation of clinical trials, officially announces a collaboration with Aditum Bio, a San Francisco-based venture endeavor firm engaged with respect to getting and creating biotechnology resources that will benefit patients. Anteris Bio in-licensed ANT-401 from vTv Therapeutics, to be studied in CKD and across multiple etiologies of renal diseases. As Aditum Bio's drug development partner, TrialSpark will support Anteris Bio utilizing its imaginative, tech-enabled clinical development model. Aditum Bio, helped to establish by previous Novartis executives Joe Jimenez and Dr. Mark Fishman, is adopting another strategy to healthcare. Aditum Bio's central goal is to give huge patient populaces admittance to medicines which in any case may not be created. To improve access for patients and speed these drugs to market, Aditum Bio makes an individual "spin-out" organization to actualize Phase I and Phase II clinical preliminaries in partnership with TrialSpark. The "spin-out" has a lean, devoted group of supervisors that can drive quickened preliminary timetables and creative preliminary plans, utilizing TrialSpark's clinical trial platform and services.

Read More

RESEARCH

Cedilla Therapeutics Expands Leadership Team with Key Appointments Across R&D And Finance

Cedilla Therapeutics | November 17, 2021

Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, announced appointments across its research and development (R&D) and finance teams, including Joshua Murtie, Ph.D., as Vice President of Biology and Chris Lindblom as Vice President of Finance. These hires are part of an ongoing initiative to expand Cedilla’s leadership and enable future growth as the company progresses its lead programs, conditional inhibitors of TEAD and CDK2, toward the clinic and continues to develop a broad portfolio of small molecule medicines that target key oncogenic drivers. “We are delighted to expand our team with these key hires, who share our passion and commitment to developing targeted medicines that conditionally modulate proteins in their functional state. We look forward to Joshua and Chris’ many contributions as we continue to explore the power of our novel approach to access historically undruggable cancer drivers, advance our lead conditional inhibitor programs targeting TEAD and CDK2 into clinical development, and ultimately build Cedilla into a fully integrated organization and leader in precision medicine.” Alexandra Glucksmann, Ph.D., President and Chief Executive Officer of Cedilla Therapeutics Joshua Murtie, Ph.D., has been appointed Vice President of Biology. Dr. Murtie brings over ten years of industry experience to Cedilla. He worked most recently as Senior Director at Servier Pharmaceuticals, where he oversaw cancer biology, in vivo pharmacology and early-stage program management at the company’s U.S. research site. Earlier, he spent nearly seven years at Agios Pharmaceuticals in roles of increasing responsibility, ultimately serving as Senior Director and Head of Cancer Biology, with responsibility for the strategic oversight of the company’s cancer biology portfolio from early target discovery to translational research. Prior to Agios Pharmaceuticals, Dr. Murtie worked as an investigator at Sanofi and Novartis. He holds a Ph.D. in molecular and cell biology from the Uniformed Services University of the Health Sciences and completed his research fellowship at Harvard Medical School. “I am thrilled to join Cedilla, particularly as we prepare to advance our lead programs, targeting TEAD and CDK2, into investigational new drug application-enabling studies next year,” said Dr. Murtie. “Both TEAD and CDK2 are well-known yet elusive cancer targets, which, if drugged successfully, could benefit the lives of patients living with a broad range of solid tumors. I am incredibly impressed by the collaborative and innovative culture at Cedilla and look forward to working closely with the team to translate our research efforts into precision therapies for patients in need.” Chris Lindblom has been appointed Vice President of Finance. Over the course of his 19 years in the biotechnology industry, Mr. Lindblom has crafted long-range financial plans for public and private companies and played a key role in helping companies raise capital through private equity rounds, venture debt deals and public offerings. Prior to joining Cedilla, Mr. Lindblom served as Vice President of Finance at IFM Therapeutics, Cogen Immune Medicine (through its merger with Torque Therapeutics to form Repertoire Immune Medicines) and Warp Drive Bio (through its acquisition by Revolution Medicines). Earlier, Mr. Lindblom held various senior finance roles at Millennium Pharmaceuticals, including through the commercial launch of VELCADE®, and at Infinity Pharmaceuticals. He also served as Vice President of Finance at OvaScience and Senior Vice President of Finance and Administration at BIND Therapeutics. Mr. Lindblom holds an MBA from Boston College and a B.S. in accounting from Syracuse University. He is also a CPA. “Since its founding, Cedilla has attracted a strong team, including leading scientists and advisors and a robust investor syndicate, to support its mission to bring a new dimension to precision oncology and deliver medicines that can offer profound benefits to patients,” said Mr. Lindblom. “I am honored to take on this role and eager to partner with my new colleagues as we continue building Cedilla for its next phase of growth.” About Cedilla Therapeutics Cedilla Therapeutics is bringing a new dimension to precision oncology. We have discovered new ways to selectively inhibit oncogenic drivers with small molecules that conditionally modulate proteins in their functional state. Our conditional inhibitors are unlocking critical and elusive cancer targets including TEAD and CDK2. We are a driven and patient-focused team.

Read More